Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
| 20.41 | |
| 20.35 | |
| - | |
| 20.44 | |
| 20.32 | |
| 14.2498-22.174 | |
| 66 971 M | |
| 29.4928 | |
| 3 291 M | |
| 1 036 076 M | |
| 0.0132 | |
| 0.507 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend i...
The S&P 500, Nasdaq Composite and Dow industrials all ended higher after data showed the U.S. defied projections of a recession last year. Continue reading
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
